Objective: To compare the efficacy and tolerability of lithium versus quetiapine for the treatment of manic or mixed episodes in youths with early course bipolar I disorder. Methods: Six-week, randomized, double-blind clinical trial of lithium versus quetiapine for the treatment of adolescents with acute manic/mixed episode. Target dose of quetiapine dose was adjusted to a target dose of 400-600 mg and target serum level for lithium was 1.0-1.2 mEq/L. Primary outcome measure was baseline-to-endpoint change in the Young Mania Rating Scale (YMRS). Secondary outcomes were treatment response (50% or more decrease from baseline in YMRS score) and remission (YMRS score ≤12, Children's Depression Rating Scale-Revised [CDRS-R] total score ≤28 and Clinical Global Impression Bipolar Severity Scale [CGI-BP-S] overall score of ≤3, respectively). Results: A total of 109 patients were randomized (quetiapine = 58 and lithium = 51). Participants in the quetiapine treatment group showed a significantly greater reduction in YMRS score than those in the lithium group (-11.0 vs. -13.2; p < 0.001; effect size 0.39). Response rate was 72% in the quetiapine group and 49% in the lithium group (p = 0.012); no differences in remission rates between groups were observed. Most frequent side effects for lithium were headaches (60.8%), nausea (39.2%), somnolence (27.5%), and tremor (27.5%); for quetiapine somnolence (63.8%), headaches (55.2%), tremor (36.2%), and dizziness (36.2%) were evidenced. Participants receiving quetiapine experienced more somnolence (p < 0.001), dizziness (p < 0.05), and weight gain (p < 0.05). Conclusions: Treatment with both lithium and quetiapine led to clinical improvement. Most study participants in this study experienced a clinical response; however, less than half of the participants in this study achieved symptomatic remission. The head-to-head comparison of both treatment groups showed quetiapine was associated with a statistically significant greater rate of response and overall symptom reduction compared with lithium. Trial registration: clinicaltrials.gov NCT00893581.
Objective: To compare the efficacy and tolerability of lithium versus quetiapine for the treatment of manic or mixed episodes in youths with early course bipolar I disorder. Methods: Six-week, randomized, double-blind clinical trial of lithium versus quetiapine for the treatment of adolescents with acute manic/mixed episode. Target dose of quetiapine dose was adjusted to a target dose of 400-600 mg and target serum level for lithium was 1.0-1.2 mEq/L. Primary outcome measure was baseline-to-endpoint change in the Young Mania Rating Scale (YMRS). Secondary outcomes were treatment response (50% or more decrease from baseline in YMRS score) and remission (YMRS score ≤12, Children's Depression Rating Scale-Revised [CDRS-R] total score ≤28 and Clinical Global Impression Bipolar Severity Scale [CGI-BP-S] overall score of ≤3, respectively). Results: A total of 109 patients were randomized (quetiapine = 58 and lithium = 51). Participants in the quetiapine treatment group showed a significantly greater reduction in YMRS score than those in the lithium group (-11.0 vs. -13.2; p < 0.001; effect size 0.39). Response rate was 72% in the quetiapine group and 49% in the lithium group (p = 0.012); no differences in remission rates between groups were observed. Most frequent side effects for lithium were headaches (60.8%), nausea (39.2%), somnolence (27.5%), and tremor (27.5%); for quetiapine somnolence (63.8%), headaches (55.2%), tremor (36.2%), and dizziness (36.2%) were evidenced. Participants receiving quetiapine experienced more somnolence (p < 0.001), dizziness (p < 0.05), and weight gain (p < 0.05). Conclusions: Treatment with both lithium and quetiapine led to clinical improvement. Most study participants in this study experienced a clinical response; however, less than half of the participants in this study achieved symptomatic remission. The head-to-head comparison of both treatment groups showed quetiapine was associated with a statistically significant greater rate of response and overall symptom reduction compared with lithium. Trial registration: clinicaltrials.gov NCT00893581.
Authors: Nick C Patel; Melissa P DelBello; Kim M Cecil; Caleb M Adler; Holly S Bryan; Kevin E Stanford; Stephen M Strakowski Journal: Biol Psychiatry Date: 2006-11-01 Impact factor: 13.382
Authors: Charles L Bowden; Heinz Grunze; Jamie Mullen; Martin Brecher; Björn Paulsson; Martin Jones; Mårten Vågerö; K Svensson Journal: J Clin Psychiatry Date: 2005-01 Impact factor: 4.384
Authors: R A Kowatch; T Suppes; T J Carmody; J P Bucci; J H Hume; M Kromelis; G J Emslie; W A Weinberg; A J Rush Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-06 Impact factor: 8.829
Authors: Annette Heinrich; Anne Sophie von der Heyde; Ulrike Böer; Do Thanh Phu; Mladen Tzvetkov; Elke Oetjen Journal: Cell Signal Date: 2012-09-18 Impact factor: 4.315
Authors: Benedetto Vitiello; Mark A Riddle; Gayane Yenokyan; David A Axelson; Karen D Wagner; Paramjit Joshi; John T Walkup; Joan Luby; Boris Birmaher; Neal D Ryan; Graham Emslie; Adelaide Robb; Rebecca Tillman Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-07-31 Impact factor: 8.829
Authors: Melissa P Delbello; Michael L Schwiers; H Lee Rosenberg; Stephen M Strakowski Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Tina R Goldstein; Boris Birmaher; David Axelson; Benjamin I Goldstein; Mary Kay Gill; Christianne Esposito-Smythers; Neal D Ryan; Michael A Strober; Jeffrey Hunt; Martin Keller Journal: J Affect Disord Date: 2008-08-20 Impact factor: 4.839
Authors: Wenbin Li; Du Lei; Maxwell J Tallman; Yuan Ai; Jeffrey A Welge; Thomas J Blom; David E Fleck; Christina C Klein; Luis R Patino; Jeffrey R Strawn; Qiyong Gong; Stephen M Strakowski; John A Sweeney; Caleb M Adler; Melissa P DelBello Journal: J Am Acad Child Adolesc Psychiatry Date: 2022-01-25 Impact factor: 13.113